On November 7, 2022 Incyte (Nasdaq:INCY) reported that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually (Press release, Incyte, NOV 7, 2022, View Source [SID1234623298]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud of the progress being made across our earlier-stage clinical programs, spanning small molecules, monoclonal and bispecific antibodies"
"We are proud of the progress being made across our earlier-stage clinical programs, spanning small molecules, monoclonal and bispecific antibodies," said Lance Leopold, M.D., Group Vice President, Clinical Development Hematology and Oncology at Incyte. "We look forward to presenting data at the SITC (Free SITC Whitepaper) Annual Meeting from our immuno-oncology pipeline, including our oral PD-L1 program, as we make progress toward our goal of identifying new solutions for patients with cancer who need additional options."
Key abstracts include:
Poster Presentations
All accepted odd-numbered posters are available from 9:00 a.m. – 9:00 p.m. EST on Thursday, November 10. All accepted even-numbered posters are available Friday, November 11, from 9:00 a.m.–8:30 p.m. EST.
INCB099280 (PD-L1)
A Phase 1 Study Exploring the Safety and Tolerability of the PD-L1 Small Molecule Inhibitor INCB099280 in Patients with Select Advanced Solid Tumors (Abstract #734)
INCB099318 (PD-L1)
A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor, INCB099318, in Patients with Select Advanced Solid Tumors (Abstract #662)
INCB086550 (PD-L1)
A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor, INCB086550, in Patients with Select Advanced Tumors (Abstract #774)
INCA32459 (LAG3xPD-1)
Phase 1 First-in-Human, Open-Label, Multicenter Study of INCA32459, a Bispecific Anti–PD1 and Anti–LAG-3 Antibody, in Patients with Select Advanced Malignancies (Abstract #723)
A Human Bispecific Antibody Targeting LAG-3 and PD-1 (INCA32459) Potently Activates Exhausted T Cells (Abstract #1210)
INCAGN01876 (GITR)
A Phase 2, Open-Label, Multicenter Study of INCAGN01876 (anti-GITR agonist) in Combination with Retifanlimab (anti–PD-1) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Abstract #677)
Bispecific Antibody Research
Comparison of Four in Vitro Cytotoxicity Assays for Assessing the Potency of Bispecific Antibodies Redirecting T Cells to Kill Tumor Target Cells (Abstract #1199)
More information regarding the congress is available on the SITC (Free SITC Whitepaper) website: View Source The virtual meeting platform will be available following the conclusion of the meeting for registered attendees until Monday, Jan. 9, 2023.